The introduction of recombinant human erythropoietin (r-HuEPO) has opened new avenues in the treatment of several types of anaemia. Multiple myeloma (MM) is often associated with anaemia. While the aetiology is multifactorial, inadequate production of erythropoietin appears to play a key role in the pathogenesis of MM-associated anaemia. This has led to numerous clinical trials of r-HuEPO in an attempt to improve MM-associated anaemia. To date, around 300 patients with MM have been reported to have been treated with r-HuEPO, with an average response rate of about 64%. Responders demonstrated a significant increase in haematocrit and haemoglobin levels, a reduction in blood transfusion requirements and improved quality of life and performance status. R-HuEPO is well tolerated in such patients. While factors predictive of response to r-HuEPO have not been fully clarified, relatively low endogenous erythropoietin levels seem to be associated with a good response to r-HuEPO.
|Number of pages||7|
|Journal||Erythropoiesis: New Dimensions in the Treatment of Anaemia|
|State||Published - 1996|